Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria: * Patients with a histologically or cytologically proven diagnosis of NSCLC * Unresectable (locally advanced) stage IIIa or IIIb disease * Initial radiotherapy field of treatment to encompass greater than or equal to 30% of the esophagus * Life expectancy greater than or equal to 6 months * Estimated weight loss less than or equal to 10% in the 3 months before study randomization * Measurable disease * 18 years of age or older * Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2 * Hemoglobin (hgb) greater than or equal to 10 g/dL without transfusional support or growth factor use in the 4 weeks before study randomization * Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10\^9/L without growth factor use in the 2 weeks before study randomization * Platelet count greater than or equal to 100 x 10\^9/L * Serum bilirubin less than or equal to 1.5 x institutional upper limit of normal (ULN) * Serum creatinine less than or equal to 2.0 mg/dL (Note: Patients with a serum creatinine greater than or equal to 1.4 and less than or equal to 2.0 mg/dL must demonstrate a 24-hour urinary creatinine clearance greater than or equal to 50 mL/min) * Females of childbearing potential: negative serum or urine pregnancy test * Patient must give written informed consent before participating in any study-specific procedure, randomization, or receiving investigational product. * Patients with reproductive capability must agree to practice adequat…